Real-world effectiveness, safety, and quality of life of biosynthetic semaglutide in Pakistani adults with type 2 diabetes mellitus: a study protocol

Ethical approval has been obtained from the USM Human Research Ethics Committee and local IRBs. The study is registered with the ANZCTR (ACTRN12625000610437). Findings will be disseminated through peer-reviewed journals and policy forums to provide a clinical and assistive framework for scalable diabetes care in resource-constrained settings.<b>Trial registration:</b> Australian New Zealand Clinical Trials Registry identifier: ACTRN12625000610437.